As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...

ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

After hours: February 18 at 4:20:00 PM EST Loading Chart for CELC ...

Broking analysts have lowered their expectations on Cochlear (ASX:COH), but in the main their valuations are above the ...

This study, led by William Banks and his team, was published in Nature Aging and adds to growing evidence that the blood-brain barrier plays a key role in memory and cognitive function. While more ...

Whether you think the tech entrepreneur’s age-defying ideas are healthy or hooey, he’s attracting legions of devoted fans ...

A multi-omics study reveals that impaired branched-chain amino acid (BCAA) catabolism is a key driver of sarcopenia, suggesting it as a potential therapeutic target.

In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...